Clinical Trial Update: Intratracheal Budesonide With Surfactant to Prevent Bronchopulmmonary Dysplasia. [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating intratracheal budesonide with surfactant to prevent bronchopulmonary dysplasia in premature infants; status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchopulmonary Dysplasia
• Prematurity
• Respiratory Distress Syndrome in Premature Infant

Drugs mentioned

• Budesonide (BUDESONIDE)
• Surfactant (surfactant)

Snippet

Sponsor: Hospital Clinic of Barcelona | Conditions: Bronchopulmonary Dysplasia, Respiratory Distress Syndrome in Premature Infant | Phase 3 | Status: UNKNOWN